Recent events in India have brought the critical issue of DEG contamination in pharmaceutical products to the forefront. The tragic deaths of 23 children in Madhya Pradesh, linked to a toxic cough syrup named Coldrif, have sparked a thorough investigation. A Special Investigation Team (SIT) is currently inspecting Sresan Pharmaceuticals, the Tamil Nadu-based manufacturer of the adulterated syrup. This incident underscores ongoing challenges in drug quality control and regulatory oversight within the Indian pharmaceutical industry.
Understanding DEG Contamination in Medicines
Diethylene glycol (DEG) presents as a colorless, odorless liquid with a sweet taste. Industrially, it serves as a solvent in products like antifreeze and brake fluids. Worryingly, DEG has no place in medicines intended for human consumption. However, it frequently ends up in cough syrups when manufacturers illegally substitute it for safer, pharmaceutical-grade propylene glycol to cut production costs. Notably, laboratory tests showed Coldrif syrup contained an alarming 48.6% DEG, significantly higher than the permissible limit of 0.1%. This highlights a critical lapse in pharmaceutical quality control.
Exposure to DEG can cause severe health complications. Affected individuals often exhibit symptoms such as abdominal pain, vomiting, diarrhea, and an inability to pass urine. More critically, DEG poisoning leads to acute kidney injury, which can be fatal, especially in children. Understanding these toxicological effects is crucial for medical professionals, particularly those in pediatrics.
Investigative Actions and Regulatory Response to DEG Contamination
In response to the Coldrif tragedy, the Madhya Pradesh SIT took Ranganathan Govindan, the 75-year-old owner of Sresan Pharmaceuticals, to his Kanchipuram factory for an on-site inspection. Tamil Nadu’s drug control department had already sealed the facility. Subsequently, a joint forensic and regulatory examination will investigate how industrial-grade DEG entered the cough syrup. Investigators are determining if this occurred through deliberate substitution, a technical fault, or procedural negligence.
The 12-member SIT plans to scrutinize the factory’s automation systems, verify machine logs, and review batch production records. Their goal is to pinpoint the exact stage of contamination. Technical experts will furthermore analyze mixing, bottling, and quality control processes to ascertain whether the toxic chemical was introduced during production or via adulterated raw materials.
The Union Health Ministry has mandated strict adherence to revised Schedule M norms, which detail Good Manufacturing Practices (GMP) under the Drugs and Cosmetics Act, 1940. These updates, effective by December 31, 2025, require enhanced quality systems, including Quality Risk Management, supply chain traceability, and explicit DEG/EG testing. For those involved in pharmaceutical regulation and practice, understanding GMP is essential, and a course on pharmacy practices would be highly beneficial.
Historical Context of DEG Poisoning Incidents
Sadly, the Coldrif tragedy is not an isolated event. India has a troubling history with DEG-contaminated syrups. For example, 33 children died in Gurugram in 1998, and 17 children perished in Jammu and Kashmir in 2020 due to similar contamination. Beyond India’s borders, contaminated Indian-made cough syrups were linked to 70 child deaths in The Gambia and 18 in Uzbekistan during 2022-23. These recurring incidents highlight persistent issues within the drug regulatory framework and emphasize the urgent need for stringent quality control measures across all pharmaceutical manufacturing units, particularly those supplying the domestic market.
Frequently Asked Questions
Q1: What is Diethylene Glycol (DEG) and why is it dangerous in medicines?
DEG is an industrial solvent with a sweet taste. It is highly toxic to humans, causing severe damage to the kidneys, liver, and nervous system, and can be fatal. It should never be present in pharmaceutical products, but some manufacturers illegally substitute it for safer solvents like propylene glycol to reduce costs.
Q2: What are the symptoms of DEG poisoning?
Initial symptoms include abdominal pain, vomiting, and diarrhea. As the poisoning progresses, it can lead to acute kidney failure, inability to pass urine, headache, altered mental status, and potentially coma and death.
Q3: How are Indian authorities responding to the Coldrif tragedy?
A Special Investigation Team (SIT) is inspecting the factory of Sresan Pharmaceuticals, the manufacturer of Coldrif. The government has also mandated stricter compliance with revised Schedule M norms for Good Manufacturing Practices and initiated nationwide audits of cough syrup manufacturers to enhance drug quality control and safety.
References
- Coldrif tragedy: MP SIT takes pharma owner to TN factory for inspection – ETHealthworld.
- Three cough syrups flagged for dangerously high DEG levels: Here’s all you need to know – The Indian Express.
- Diethylene Glycol Poisoning – StatPearls.
- ToxCard: Diethylene Glycol – emDocs.
- Diethylene glycol poisoning – PubMed.
- Repeated deadly cough syrup scandals pose hard questions for India’s drug regulators – The Straits Times.
- FDA’s actions to protect children from contaminated cough medicine – U.S. Food and Drug Administration.
- Cough Syrup Deaths in India: Understanding the Contamination Crisis and Regulatory Response – Vision IAS.
- What is diethylene glycol, the toxic solvent found in cough syrups that killed kids in India – The Economic Times.
- Cough syrup contamination: Health Ministry directs strict compliance with revised Schedule M norms – The Hindu.
- Cough syrup advisory: Check names of three banned toxic syrups and five harmful ingredients parents should watch out for – The Economic Times.
- Drug regulator begins pan-Indian inspection of cough syrup makers – Business Standard.
Disclaimer: This article was automatically generated from publicly available sources and is provided for informational and educational purposes only. OC Academy does not exercise editorial control or claim authorship over this content. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider and refer to current local and national clinical guidelines.